MedTrace Logo

An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease

NCT05497765 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2024-02-28

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the patients with NAFLD.

Conditions

  • Nonalcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza

Take 4 tablets with warm water twice a day

DIETARY_SUPPLEMENT

Silibinin extract

Take 4 tablets with warm water twice a day

DIETARY_SUPPLEMENT

Placebo

Take 4 tablets with warm water twice a day

Sponsors & Collaborators

  • Affiliated Hospital of Guangdong Medical University

    collaborator OTHER

  • Guangzhou Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-01-31
Completion
2024-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05497765 on ClinicalTrials.gov